Lilly Ventures

Grove Biopharma is a biotechnology company specializing in materials science solutions for peptide therapeutics. It focuses on discovering and developing novel 'protein-like polymers' to address significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Enchannel Medical is a global innovation platform specializing in electrophysiology, particularly in the treatment of atrial fibrillation. The company has developed an integrated solution that combines advanced three-dimensional mapping with pulsed field ablation technology. Their unique four-dimensional mapping system leverages both magnetoelectric positioning contact and non-contact mapping technologies, allowing for real-time visualization of arrhythmia mechanisms during electrophysiological procedures. This innovation aims to enhance the safety and efficacy of cardiac arrhythmia surgeries, providing physicians with refined tools for better patient outcomes in the management of atrial fibrillation.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Chimagen Biosciences specializes in developing a novel class of multi-functional monoclonal antibodies for cancer therapy.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Founded in 2021, Arda Therapeutics is a biotechnology company based in the San Francisco Bay Area. It specializes in developing transformative therapeutics to eliminate pathogenic cells that drive chronic diseases and aging.

Amprion is a biotechnology company specializing in the development of diagnostic tests for brain diseases. Founded in 2007, it is headquartered in San Francisco, California. The company focuses on detecting pathological α-synuclein in cerebrospinal fluid to aid clinicians in diagnosing neurodegenerative conditions like Parkinson's and Lewy body dementia.

NanoSyrinx is a biotechnology company focused on developing a novel biologics drug delivery platform that targets therapeutic proteins and peptides to the cytosol of cells. Through synthetic biology, the company seeks to transport payloads directly into cell interiors, aiming to improve the efficacy, safety, and cost-effectiveness of treatments. The platform is designed to serve the biopharmaceutical sector by enabling targeted delivery of biologics to intracellular targets, with potential to enhance treatment outcomes across multiple indications.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Ajax Therapeutics is a New York City-based biotechnology company that applies computational chemistry and structure-based technologies to develop novel small molecules for treating hematologic malignancies.

IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

FireFly Bio is a biotechnology company focused on developing innovative therapies for cancer through its proprietary platform centered on Degrader Antibody Conjugates (DACs). This technology merges the advantages of traditional antibody-drug conjugates (ADCs) with selective protein degradation, allowing for the targeted delivery of therapeutic agents to specific tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create highly specific and effective treatments that enhance patient outcomes. The company's approach emphasizes precision in medicine, seeking to improve the potency and efficacy of cancer therapies.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Akura Medical develops next-generation thrombectomy devices designed to simplify clot removal with a single-pass procedure, offering an easy-to-use solution to efficiently remove blood clots. The company also provides a range of surgical, medical, dental, and veterinary instruments to support clinicians in addressing venous thromboembolism and other clot-related conditions across diverse patient populations.

Laverock Therapeutics develops a gene silencing platform for creating programmable, allogeneic cell therapies.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

Pixin Technology is a provider of decision-making products for medical imaging using artificial intelligence.

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.

Enchannel Medical is a global innovation platform specializing in electrophysiology, particularly in the treatment of atrial fibrillation. The company has developed an integrated solution that combines advanced three-dimensional mapping with pulsed field ablation technology. Their unique four-dimensional mapping system leverages both magnetoelectric positioning contact and non-contact mapping technologies, allowing for real-time visualization of arrhythmia mechanisms during electrophysiological procedures. This innovation aims to enhance the safety and efficacy of cardiac arrhythmia surgeries, providing physicians with refined tools for better patient outcomes in the management of atrial fibrillation.

Versanis Bio is a biopharmaceutical company focused on discovering and developing innovative medicines for medical conditions commonly affecting older adults. The company is advancing Bimagrumab, a human monoclonal antibody that targets activin type II receptors, effectively blocking ligands such as activin A and myostatin. Bimagrumab has undergone extensive clinical evaluation in over a dozen trials with more than 1,500 participants, demonstrating its ability to induce significant fat loss while preserving lean mass. Additionally, treatment with Bimagrumab has shown improvements in HbA1c levels and other cardiometabolic parameters, thereby assisting overweight and obese adults in achieving and maintaining a healthier body composition.

Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies to mimic T-cells, which are essential components of the immune system, aiming to enhance the quality of life for cancer patients. Their next-generation immunotherapies are designed to target previously unreachable cancer cell proteins with high precision, offering an efficient and selective approach to cancer treatment. By unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics seeks to dramatically expand the capabilities of antibody therapy across various cancer types, ultimately improving patient outcomes.

Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

DiogenX is a French biotechnology company founded in 2019, focused on developing therapeutic solutions for diabetic patients. It specializes in pancreatic beta-cell modulators for treating Type 1 and Type 2 diabetes by regenerating insulin-producing cells.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

ImmuneOnco Biopharma, founded in June 2015 in Zhangjiang High-Tech Park, Shanghai, is an innovative biopharmaceutical company focused on developing and commercializing novel cancer immunotherapy products. The company aims to reverse immune inhibition caused by cancer cells and actively eliminate these cells. ImmuneOnco is recognized for its systematic approach to leveraging both innate and adaptive immune systems in its research and development efforts. The company boasts a robust pipeline of 14 drug candidates, with eight currently undergoing clinical programs, highlighting its commitment to advancing immuno-oncology therapies. ImmuneOnco's extensive understanding of cancer biology and immunology enables it to transform scientific research into viable therapeutic options.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for oncology, metabolic diseases, and autoimmune diseases. The company utilizes its proprietary CARD (Computer Accelerated Rational Discovery) platform, which integrates structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development to create clinically differentiated therapeutics. With a world-class scientific team, Regor Therapeutics is committed to efficiently producing both best-in-class and first-in-class molecules, advancing its mission to improve patient outcomes through novel therapeutic solutions.

Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

MiNA Therapeutics Limited is a clinical-stage biotechnology company based in London, United Kingdom, focused on the design and development of small activating RNA medicines aimed at restoring normal cellular function. Founded in 2008, the company is dedicated to harnessing gene activation mechanisms to create therapeutic solutions for cancer and other severe diseases. Its product pipeline includes MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA paired with Pembrolizumab for advanced solid tumors. Through its innovative approach, MiNA Therapeutics aims to transform the treatment landscape, enabling healthcare professionals to effectively address challenging medical conditions.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Duality Biologics is a biopharmaceutical company focused on oncology and autoimmune diseases, developing novel modality drugs that include antibody-drug conjugates and bispecific antibodies. It operates a sizable internal pipeline of ADCs and bispecific candidates, with multiple programs in clinical development and several preclinical assets. The company has built a next-generation ADC platform with broad global intellectual property rights and aims to translate novel modalities into approved therapies. Its pipeline comprises numerous in-house ADC candidates, including seven clinical-stage ADCs and two next-generation bispecific ADCs, with additional preclinical programs, and some assets have received regulatory designations such as Fast Track.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Founded in 1996, Sichuan Kelun Pharmaceutical is a Chinese company engaged in the research, development, manufacture, distribution, and sale of pharmaceutical products. Its primary focus is on infusion products, antibiotics, and medical devices.

NovoCodex is involved in the research, development, and manufacture of biological products. Its mission is to provide cutting-edge technology to meet clinical needs. In Binhai New City Science and Technology Park, the company has established a biopharmaceutical laboratory with experience and capabilities in genetic engineering construction, cell culture, toxin synthesis, ADC coupling, preparation filling, preclinical research, and clinical research.